Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Nanostart AG
www.nanostart.de
Deal Nanostart AG Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

We undertake equity investments in emerging nanotechnology companies which hold the potential to deliver extraordinary long-term growth. The typical size of our investments is between one and ten million Euros.

Pdf

Warburg Research reiterates Nanostart's buy rating

Nanotechnology investor Nanostart (OTCQX: NNS, NASRY) had its 'buy' rating reiterated by equity research firm Warburg Research on Friday, following Nanostart's recent sale and acquisition of various company interests.

Venture investor Nanostart, through its Singapore-based early stage fund, recently sold its stake in Curiox, which it acquired in 2007, earlier than originally expected. According to Nanostart, a small profit was made from the deal, which will flow back into the fund's assets, and will therefore not be distributed as dividends or have a corresponding impact on earnings, said Warburg.

In December, Nanostart also announced the acquisition of a 19% stake in Microlight Sensors, a company that develops and produces sensors and optical systems, particularly focusing on safety-relevant applications in extremely low
lighting conditions.

Warburg said that Microlight could generate sales "to the tune of EUR 15- 20 m in the next 4-5 years with an extended product portfolio". This would mean a value of EUR20 million for the company, of which approximately EUR2 million would be alloted to Nanostart's share, according to Warburg's calculations.

Nevertheless, Nanostart's portfolio is still driven by its largest investment, MagForce, in which it holds a 70% stake. Berlin-based MagForce has developed a treatment for tumours using magnetic nano particles, and has recently received EU approval for brain tumour therapy. In this indication alone, the company is likely to acheive peak sales of EUR150 million.

"The realisation of commercial marketing is likely to be focussed in 2011 at Magforce, from which positive newsflow is expected to result in the next months," Warburg added.

In addition to MagForce, Nanostart has other investments in the fields of medical technology and diagnostics, as well as electrical engineering and environmentally-friendly technology. It has exited eight of the nineteen investments it has made thus far.

Frankfurt-based Nanostart is currently trading at $19.30 - up nearly 8% today. Warburg's price target for the investment firm is $35.00.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.